Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 10/2015

01-10-2015 | Psoriatic Arthritis (O FitzGerald and P Helliwell, Section Editors)

Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence

Authors: Alexis Ogdie, J. M. Gelfand

Published in: Current Rheumatology Reports | Issue 10/2015

Login to get access

Abstract

Psoriatic arthritis (PsA), a chronic inflammatory arthritis, affects about 10 % of patients with psoriasis with higher prevalence seen in patients with more extensive skin disease. Early identification of PsA may result in improved outcomes. While it remains unclear which patients with psoriasis will develop PsA, several studies have identified potential risk factors for PsA among patients with psoriasis. This review examines the basic epidemiologic principles of identifying risk factors and reviews the evidence to date about risk factors for PsA among patients with psoriasis.
Literature
1.
Kurd S, Gelfand J. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60(2):218–24.CrossRefPubMed
2.
Alamanos Y, Voulgari P, Drosos A. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol. 2008;35(7):1354–8.PubMed
3.
Ibrahim G, Waxman R, Helliwell P. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61(10):1373–8.CrossRefPubMed
4.
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.PubMed
5.
Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford). 2013;52(3):568–75.CrossRef
6.
Mease P, Gladman D, Papp K, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–35.CrossRefPubMed
7.•
Fitzgerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17(1):115. While our review discusses the clinical risk factors for PsA, this is an excellent review of the genetic risk factors for psoriatic arthritis and the interplay between genotypes and phenotypes in psoriatic arthritis. PubMedCentralCrossRefPubMed
8.
Fletcher RH, Fletcher SW, Fletcher GS. Risk: basic principles. In: clinical epidemiology: the essentials. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2014. p. 50–79.
9.
10.
11.
Ogdie A, Weiss PF. Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am 2015; In Press.
12.
Wu S, Han J, Qureshi AA. Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study. Acta Derm Venereol. 2015;95(2):217–23.PubMedCentralCrossRefPubMed
13.••
Wu S, Li WQ, Han J, Sun Q, Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthrit Rheumatol. 2014;66(2):304–10. In this retrospective cohort study, Wu et al. found an increased incidence of both psoriasis and psoriatic arthritis among patients with physician-diagnosed hypercholesterolemia. In contrast, there was no association with cholesterol-lowering medications. CrossRef
14.
Tong LX, Wu S, Li T, Qureshi AA, Giovannucci EL, Cho E. Personal history of gallstones and risk of incident psoriasis and psoriatic arthritis in U.S. women. Br J Dermatol. 2015;172(5):1316–22.PubMedCentralCrossRefPubMed
15.
Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–40.CrossRefPubMed
16.
Gelfand J, Gladman D, Mease P, et al. Epidemiology of psoriatic arthritis in the population of the US. 2005; 53:573–7.
17.
Wilson F, Icen M, Crowson C, McEvoy M, Gabriel S, Kremers H. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233–9.PubMedCentralCrossRefPubMed
18.
Soltani-Arabshahi R, Wong B, Feng B, Goldgar D, Duffin K, Krueger G. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010;146(7):721–6.CrossRefPubMed
19.
Tey H, Ee H, Tan A, Theng T, Wong S, Khoo S. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 2010;37(5):426–30.CrossRefPubMed
20.
Anandarajah A, Ritchlin C. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol. 2004;16(4):338–43.CrossRefPubMed
21.
Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandía JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46(6):867–73.CrossRefPubMed
22.
Stuart P, Malick F, Nair RP, et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res. 2002;294(5):207–13.CrossRefPubMed
23.
McGonagle D, Palmou Fontana N, Tan A, Benjamin M. Nailing down the genetic and immunological basis for psoriatic disease. Dermatology. 2010;221 Suppl 1:15–22.CrossRefPubMed
24.
Love T, Gudjonsson J, Valdimarsson H, Gudbjornsson B. Psoriatic arthritis and onycholysis—results from the cross-sectional Reykjavik psoriatic arthritis study. J Rheumatol. 2012;39(7):1441–4.CrossRefPubMed
25.
Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006;33(7):1315–9.PubMed
26.
Thumboo J, Uramoto K, Shbeeb M, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. J Rheumatol. 2002;29(4):757–62.PubMed
27.
Thijssen E, van Caam A, van der Kraan P. Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue anddyslipidaemia in obesity-induced osteoarthritis. Rheumatology (Oxford). 2015;54(4):588–600.CrossRef
28.
Kumar S, Han J, Li T, Curhan G, Choi HK, Qureshi AA. Obesity, waist circumference, weight change, and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2013;27(10):1293–8.PubMedCentralPubMed
29.
30.
31.
Ogdie A, Gelfand JM. Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need. Arch Dermatol. 2010;146(7):785–8.PubMedCentralCrossRefPubMed
32.
33.
Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010;69(1):70–81.CrossRefPubMed
34.
Eder L, Shanmugarajah S, Thavaneswaran A, et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2012;71(2):219–24.CrossRefPubMed
35.
Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(8):1091–7.CrossRef
36.
Pattison E, Harrison B, Griffiths C, Silman A, Bruce I. Environmental risk factors for the development of psoriatic arthritis: results from a case–control study. Ann Rheum Dis. 2008;67(5):627–6.
37.
38.
Wu S, Cho E, Li WQ, Han J, Qureshi AA. Alcohol intake and risk of incident psoriatic arthritis in women. J Rheumatol. 2015;42(5):835–40.CrossRefPubMed
39.
Scott I, Tan R, Stahl D, Steer S, Lewis C, Cope A. The protective effect of alcohol on developing rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52(5):856–67.CrossRef
40.
McGonagle D, Ash Z, Dickie L, McDermott M, Aydin S. The early phase of psoriatic arthritis. Ann Rheum Dis. 2011;70 Suppl 1:i71–6.CrossRefPubMed
41.•
Manasson J, Scher J. Spondyloarthritis and the microbiome: new insights from an ancient hypothesis. Curr Rheumatol Rep. 2015;17(2):10. This review paper highlights the potential role of the microbiome (both the intestinal and skin microbiome) in the development of the spondyloarthropathies. CrossRefPubMed
42.•
Eder L, Chandran V, Shen H. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken). 2011;63(4):619–22. Describes the first prospective longitudinal study to examine the incidence of PsA among patients with psoriasis. CrossRef
Metadata
Title
Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence
Authors
Alexis Ogdie
J. M. Gelfand
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 10/2015
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0540-1
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits